Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of Dual and Selective Degraders of Cyclin-Dependent Kinases 4 and 6
Authors
Keywords
-
Journal
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2019-02-26
DOI
10.1002/anie.201901336
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Plasticity in binding confers selectivity in ligand-induced protein degradation
- (2018) Radosław P. Nowak et al. Nature Chemical Biology
- Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome
- (2018) Katherine A Donovan et al. eLife
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs
- (2018) Sainan An et al. EBioMedicine
- Bruton's Tyrosine Kinase degradation as a therapeutic strategy for cancer
- (2018) Dennis Dobrovolsky et al. BLOOD
- Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN
- (2018) Quinlan L. Sievers et al. SCIENCE
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation
- (2017) Calla M Olson et al. Nature Chemical Biology
- CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib
- (2017) Bahar Laderian et al. SEMINARS IN ONCOLOGY
- pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
- (2017) Jian An et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- Small-Molecule PROTACS: New Approaches to Protein Degradation
- (2016) Momar Toure et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Cyclin-Dependent Kinase 6 Is a Chromatin-Bound Cofactor for NF-κB-Dependent Gene Expression
- (2014) Katja Handschick et al. MOLECULAR CELL
- A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
- (2013) Karoline Kollmann et al. CANCER CELL
- Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells
- (2013) J. Kronke et al. SCIENCE
- The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
- (2013) G. Lu et al. SCIENCE
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started